FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.3548
Abstract: 3548Background: The treatment of metastatic colorectal cancer (mCRC) pts with BRAF-mut tumors is a major challenge for physicians. They account for < 10% of mCRC, correlate with poor prognosis, and... read more here.
Keywords: folfirinox plus; cet bevacizumab; cetuximab cet; plus cetuximab ... See more keywords